News

12. Mai 2015

Probiodrug to hold its Annual Shareholders Meeting on June 10, 2015 

12. Mai 2015

Probiodrug AG to publish its First Quarter 2015 Business Update on May 13, 2015

12. Mai 2015

Probiodrug to Present at Drug Design & Medicinal Chemistry Conference 2015
GTC 9th Drug Design & Medicinal Chemistry Conference, 5-6 May 2015, Berlin, Germany

24. April 2015

Key patents on Glutaminyl Cyclase (QC) inhibition for the treatment of Alzheimer's disease granted in Japan

Patent grants strengthen IP position in Japan and follow issuance and grants in other important markets such as USA and Europe

24. April 2015

Nature Communications Publications on the First X-ray Crystal Structures of Spiegelmers Bound to Protein Targets
Anti-CCL2 and anti-C5a Spiegelmers Revealed in Complex with Their Targets

31. März 2015

Probiodrug reports full year 2014 financial results

20. März 2015

Probiodrug to present data on its Anti-pGlu-3 Abeta monoclonal Antibody at the 12th International Conference on Alzheimer's and Parkinson's Diseases (AD/PDTM 2015), Nice 

9. März 2015

Probiodrug announces enrolment of first patient in Phase 2 Study of novel Treatment for Alzheimer's disease

3. März 2015

Data on Glutaminyl Cyclases (QCs) in its relation to Alzheimer's Disease (AD) published in Acta Neuropathologica

25. Februar 2015

Probiodrug to present at European Life Sciences Conferences

Seiten